CSIMarket Company Name, Ticker, Suppliers, else..
 

Celgene Corp  (NASDAQ: CELG)

Celgene's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

CELG Sales vs. its Competitors Q3 2019


Comparing the current results to its competitors, Celgene reported Revenue increase in the 3 quarter 2019 by 16.14 % year on year.
The sales growth was above Celgene's competitors' average revenue growth of 16.13 %, achieved in the same quarter.

• List of CELG Competitors

With a net margin of 37.41 % Celgene achieved higher profitability than its competitors.

• More on CELG Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison

Celgene Corp Net Income in the 3 quarter 2019 grew year on year by 56.28%, faster than the Celgene's competitors average income growth of 55.76 %

<<  CELG Stock Performance Comparisons





  

Overall company Market Share Q3 2019
Overall company sales advanced by 16.14 % and Celgene increased its market share in Overall company segment.
<<  More on CELG Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Celgene Corp




Allarity Therapeutics Inc
Share Performance



-31.29%
One Year
Allarity Therapeutics Inc
Profile

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

More about Allarity Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 17.820 mill. $ - mill. $ -12.334 mill.


Briacell Therapeutics Corp
Share Performance



+18.08%
30 Days
Briacell Therapeutics Corp
Profile

Briacell Therapeutics Corp's business model is centered around the development and commercialization of personalized immunotherapies for the treatment of cancer.

More about Briacell Therapeutics Corp 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 29.621 mill. $ - mill. $ -30.976 mill.


C4 Therapeutics Inc
Share Performance



+69.17%
This Year
C4 Therapeutics Inc
Profile

C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.

More about C4 Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 426.725 mill. $ 35.039 mill. $ -101.416 mill.


Greenwich Lifesciences Inc
Share Performance



-3.44%
This Year
Greenwich Lifesciences Inc
Profile

Greenwich Lifesciences Inc's business model focuses on the research, development, and commercialization of innovative therapies in the field of oncology.

More about Greenwich Lifesciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 274.879 mill. $ - mill. $ -22.398 mill.


Ladrx Corporation
Share Performance



0.00%
Over The Past 5 Days
Ladrx Corporation
Profile

Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.

More about Ladrx Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.005 mill. $ - mill. $ -2.496 mill.

Sources: Celgene Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Celgene Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.